ImmunovantIMVT
About: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Employees: 207
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
232% more call options, than puts
Call options by funds: $59.7M | Put options by funds: $18M
40% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]
12% more capital invested
Capital invested by funds: $2.01B [Q2] → $2.24B (+$234M) [Q3]
1.67% more ownership
Funds ownership: 52.06% [Q2] → 53.73% (+1.67%) [Q3]
8% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 65
8% less funds holding
Funds holding: 195 [Q2] → 180 (-15) [Q3]
42% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 36
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
HC Wainwright & Co. Douglas Tsao 58% 1-year accuracy 93 / 161 met price target | 92%upside $51 | Buy Reiterated | 8 Nov 2024 |
Raymond James Danielle Brill 73% 1-year accuracy 11 / 15 met price target | 35%upside $36 | Outperform Reinstated | 10 Oct 2024 |
Oppenheimer Leland Gershell 58% 1-year accuracy 35 / 60 met price target | 99%upside $53 | Outperform Maintained | 9 Oct 2024 |
HC Wainwright & Co. Douglas Tsao 58% 1-year accuracy 93 / 161 met price target | 92%upside $51 | Buy Reiterated | 30 Sept 2024 |
HC Wainwright & Co. Douglas Tsao 58% 1-year accuracy 93 / 161 met price target | 92%upside $51 | Buy Reiterated | 10 Sept 2024 |
Financial journalist opinion
Based on 3 articles about IMVT published over the past 30 days
